Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From SparingVision
The French biotech has managed to bag a blue-chip partner to advance its ambitions to be the leading company in the ocular genomic medicine space, getting access to Intellia's CRISPR/Cas9 technology.
Also, Atlas Venture and Advent France Biotechnology raise new venture capital funds, Corium secures $235m in debt to commercialize ADHD drug and CBMG leads recent VC financings with $120m series A round.
Private Company Edition: Jeito says its new first fund is Europe’s largest life science-focused fund. Illumina will use its venture capital to support tools, diagnostics, therapeutics and more. Also, IASO closed a $108m series C round and Amolyt raised $80m in series C financing.
Building on 20 years of work and positive preclinical data, and backed by a fresh injection of cash, Alentis is taking its liver fibrosis candidate into Phase I trials in the fourth quarter.
- Gene Therapy, Cell Therapy
Drug Discovery Tools